Stock Track | Tandem Diabetes Care Soars 9.29% in Pre-Market on BofA Upgrade and Strong Q4 Earnings Beat

Stock Track

Feb 20

Tandem Diabetes Care's stock surged 9.29% during pre-market trading following a significant analyst upgrade and the release of its fourth-quarter financial results, which handily exceeded Wall Street expectations.

The pre-market rally was fueled by BofA's decision to upgrade Tandem Diabetes Care to Neutral from Underperform, while more than doubling its price target to $30 from $15. This bullish move from the analyst firm provided a major catalyst for investor sentiment.

Further supporting the price movement were the company's Q4 2025 earnings, which showed a net loss of just $0.01 per diluted share, significantly better than the $0.09 per share loss anticipated by analysts polled by FactSet. Quarterly sales of $290.4 million also surpassed the $277 million consensus estimate, demonstrating stronger-than-expected revenue performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1184159489"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1184159489\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1184159489?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 20:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184159489","market":"us","top_or_hot":-1,"title":"Stock Track | Tandem Diabetes Care Soars 9.29% in Pre-Market on BofA Upgrade and Strong Q4 Earnings Beat","media":"Stock Track","content":"<p>Tandem Diabetes Care's stock surged 9.29% during pre-market trading following a significant analyst upgrade and the release of its fourth-quarter financial results, which handily exceeded Wall Street expectations.</p><p>The pre-market rally was fueled by BofA's decision to upgrade Tandem Diabetes Care to Neutral from Underperform, while more than doubling its price target to $30 from $15. This bullish move from the analyst firm provided a major catalyst for investor sentiment.</p><p>Further supporting the price movement were the company's Q4 2025 earnings, which showed a net loss of just $0.01 per diluted share, significantly better than the $0.09 per share loss anticipated by analysts polled by FactSet. Quarterly sales of $290.4 million also surpassed the $277 million consensus estimate, demonstrating stronger-than-expected revenue performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tandem Diabetes Care Soars 9.29% in Pre-Market on BofA Upgrade and Strong Q4 Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tandem Diabetes Care Soars 9.29% in Pre-Market on BofA Upgrade and Strong Q4 Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-20 20:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tandem Diabetes Care's stock surged 9.29% during pre-market trading following a significant analyst upgrade and the release of its fourth-quarter financial results, which handily exceeded Wall Street expectations.</p><p>The pre-market rally was fueled by BofA's decision to upgrade Tandem Diabetes Care to Neutral from Underperform, while more than doubling its price target to $30 from $15. This bullish move from the analyst firm provided a major catalyst for investor sentiment.</p><p>Further supporting the price movement were the company's Q4 2025 earnings, which showed a net loss of just $0.01 per diluted share, significantly better than the $0.09 per share loss anticipated by analysts polled by FactSet. Quarterly sales of $290.4 million also surpassed the $277 million consensus estimate, demonstrating stronger-than-expected revenue performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNDM","symbol_name":"Tandem Diabetes","start_time":0,"source_url":"","article_id":"1184159489","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184159489","pubTimestamp":1771590301,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Tandem Diabetes Care's stock surged 9.29% during pre-market trading following a significant analyst upgrade and the release of its fourth-quarter financial results, which handily exceeded Wall Street...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TNDM":"Tandem Diabetes"},"translate_title":"股票追踪|Tandem Diabetes Care盘前飙升9.29%，因美国银行升级和强劲的第四季度盈利超出预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNDM":1},"content_text":"Tandem Diabetes Care's stock surged 9.29% during pre-market trading following a significant analyst upgrade and the release of its fourth-quarter financial results, which handily exceeded Wall Street expectations.The pre-market rally was fueled by BofA's decision to upgrade Tandem Diabetes Care to Neutral from Underperform, while more than doubling its price target to $30 from $15. This bullish move from the analyst firm provided a major catalyst for investor sentiment.Further supporting the price movement were the company's Q4 2025 earnings, which showed a net loss of just $0.01 per diluted share, significantly better than the $0.09 per share loss anticipated by analysts polled by FactSet. Quarterly sales of $290.4 million also surpassed the $277 million consensus estimate, demonstrating stronger-than-expected revenue performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}